Riskpilot← Back to searchSign inGet full accessNORDIC PHARMACEUTICALS ApS
APSActiveCVR 27430015Hammerholmen 44Manufacture of other food products n.e.c. · NACE 1089Est. 20031 employees
Revenue 2024
DKK -2,2M
-506% vs 2023
EBITDA margin
114.0%
-1793% vs 2023
Equity ratio
-5211.1%
Financial strength
Net profit 2024
DKK -2,7M
-28593% vs 2023
| Revenue | DKK -2,2M | -506% |
| EBITDA | DKK -2,6M | -1793% |
| Net profit | DKK -2,7M | -28593% |
| Total assets | DKK 22K | -99% |
| Equity | DKK -1,2M | -176% |
| Employees | 1 | — |
Legal name
NORDIC PHARMACEUTICALS ApS
CVR number
27430015
Legal form
Anpartsselskab
NACE code
1089 · Manufacture of other food products n.e.c.
Founded
12. november 2003
Share capital
DKK 200.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af formanden for bestyrelsen i forening med en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive virksomhed inden for salg, pakning og fremstilling af lægemidler og kosttilskud samt anden virksomhed, som har forretningsmæssig sammenhæng hermed.
Address
Hammerholmen 44
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 959 | 808 | 899 | 1.296 | 1.436 | 1.038 | 1.063 | 1.269 | 602 | 653 | 779 | 552 | -2.243 |
| Staff expenses | -522 | -524 | -709 | -806 | -1.207 | -913 | -945 | -1.145 | -439 | -492 | -574 | -401 | -314 |
| EBITDA | 437 | 285 | 190 | 393 | 229 | 125 | 118 | 124 | 163 | 161 | 205 | 151 | -2.558 |
| Depreciation & amort. | -2 | -5 | -6 | -5 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 435 | 280 | 184 | 387 | 229 | 125 | 118 | 124 | 163 | 161 | 205 | 151 | -2.558 |
| Net financials | -47 | -28 | -61 | -65 | -44 | -70 | -74 | -91 | -89 | -69 | -97 | -106 | -107 |
| Profit before tax | 388 | 252 | 122 | 323 | 185 | 55 | 44 | 33 | 74 | 92 | 108 | 45 | -2.664 |
| Tax | -33 | 63 | -29 | 41 | 40 | 14 | 10 | 7 | 16 | 20 | 24 | 36 | -0 |
| Net profit | 421 | 190 | 152 | 282 | 145 | 40 | 34 | 26 | 58 | 71 | 84 | 9 | -2.664 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.789 | 1.651 | 2.320 | 3.591 | 3.759 | 2.533 | 2.734 | 3.126 | 2.062 | 2.605 | 2.891 | 2.579 | 22 |
| Equity | 614 | 611 | 762 | 1.044 | 1.189 | 1.229 | 1.263 | 1.289 | 1.347 | 1.419 | 1.503 | 1.512 | -1.153 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1.175 | 1.041 | 1.558 | 2.547 | 2.570 | 1.304 | 1.470 | 1.836 | 715 | 1.186 | 1.388 | 1.067 | 1.175 |
| Total debt | 1.175 | 1.041 | 1.558 | 2.547 | 2.570 | 1.304 | 1.470 | 1.836 | 715 | 1.186 | 1.388 | 1.067 | 1.175 |
EBITDA margin
-255753900.0%
This company
15.8%
Market median
-1618695670% vs market
20122024
Equity ratio
-5211.1%
This company
38.2%
Market median
-13742% vs market
20122024
Return on equity
-266441600.0%
This company
18.4%
Market median
-1448052274% vs market
20122024
Net profit margin
-266441600.0%
This company
8.1%
Market median
-3289402569% vs market
20122024
Asset turnover
-101.43×
This company
1.12×
Market median
-9156% vs market
20122024
Debt / equity
1.02×
This company
0.62×
Market median
-65% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JR Management | Management | 2003 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2003 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 50.0% | 50.0% | 2015 | |
| Individual | 50.0% | 50.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NORDIC PHARMACEUTICALS ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Renneberg | Management | 0 companies |
| Knud Benny Junge | Chairman | 0 companies |